Educating the patient, controlling the disease: a point prevalence evaluation of structured pharmaceutical asthma care in real world settings Authors: Maja Simonoska Crcarevska, Zorica Naumovska, Beti Zafirova Ivanovska, Biljana Bozhinovska, Joana Andonoska, Sashka Janevska, Siân Williams, Jaime Correia-de-Sousa, Katarina Stavriкј Published: 2026 ABSTRACT Asthma control remains suboptimal worldwide, often due to modifiable factors such as incorrect inhaler technique and reliever overuse. Community pharmacists (CPs) are well-positioned to address these gaps through structured patient education. A point prevalence evaluation was conducted in 1247 patients across 127 community pharmacies (11.1% of all pharmacies) in North Macedonia (Dec 2023–Sep 2024). Asthma control was assessed using the Asthma Control Test (ACT), while Asthma Slide Rule (ASR) was used to evaluate short-acting beta-agonists (SABAs) use. Inhaler technique was assessed using device-specific checklists. CPs provided comprehensive care, including adherence support, lifestyle counselling, and monitoring. Poor inhaler technique strongly predicted poor asthma control (ACT: OR = 5.98; ASR: OR = 6.43). Among 127 patients followed, correct technique improved from 71.7% at baseline to 88.8% at the second visit, and among patients who attended all three visits, accuracy increased from ∼63% at the first visit to∼89% at the second and 98.2% at the third (56 patients). By the third visit, the association between technique and control diminished, reflecting the success of comprehensive pharmaceutical care. These results highlight the critical, multifaceted role of CPs in improving asthma outcomes and support the integration of CP-led comprehensive pharmaceutical care for asthma into national management strategies. Introduction Asthma is a chronic inflammatory airway disease that affects millions worldwide and imposes a significant burden on healthcare systems, patients, and communities. Despite well-established treatment guidelines and the widespread availability of effective inhaled therapies, many patients continue to experience poor asthma control1–3 This is often due to modifiable factors, such as inappropriate use of reliever medication, incorrect inhaler technique and poor adherence to controller therapy4. Global evidence has demonstrated the pivotal role of correct inhaler technique in achieving optimal treatment outcomes. Even when appropriate medications are prescribed, improper inhaler use can markedly reduce pulmonary drug distribution, thus limiting therapeutic efficacy and increasing the risk of symptom exacerbation and poor disease control5,6. Additionally, the overuse of short-acting beta-agonists (SABAs) as “rescue (reliever)” medications remains a global concern. Frequent SABA use is not only a marker of poor control but is also associated with increased morbidity and mortality when not accompanied by adequate controller therapy. Adequate controller therapy is generally considered to be inhaled corticosteroids (ICS) alone or in combination with long-acting bronchodilators7,8. Pharmacists, as highly accessible and skilled healthcare professionals, are well-positioned to address these issues through patient-centred pharmaceutical care. In recent years, the pharmacist’s role has evolved and includes active participation in chronic disease management, including asthma9. Multiple studies from various health systems have shown that pharmacist-led interventions such as inhaler technique assessment, education on medication use, counselling on lifestyle modifications, and follow-up monitoring can improve asthma outcomes, increase adherence, and reduce unnecessary healthcare costs10–13. The finding of benefit associated with pharmacist-led asthma care aligns with recent perspectives highlighting the need for a multidisciplinary approach in asthma care, where pharmacists play a central role in bridging gaps between patients and physicians and in reinforcing adherence and self-management strategies14. Despite these recommendations, evidence from real-world practice remains limited in many countries, underscoring the need for structured and context-specific initiatives to fully integrate pharmacists into long-term asthma care pathways14. The prevalence of asthma in Macedonia is estimated to be 5.4% among adults aged 20–4415, and according to WHO data from 2020, it is 1.6 per 100,000 inhabitants16. According to data obtained from the National Electronic Health Records System” My Term (Moj Termin)”, for 2022, the prevalence of patients recorded with asthma ≥ 18 years is 18296, i.e. 1.3% prevalence, which indicates underdiagnosis of asthma. Epidemiologic prevalence estimates are presented to contextualize the national asthma burden. The estimates and are not intended as reference standards for clinical or outcome analyses in this study. In North Macedonia, a national initiative was launched in 2023 to integrate community pharmacists (CPs) into structured asthma care, as part of the broader Asthma Right Care movement initiated by the International Primary Care Respiratory Group (IPCRG) and supported by academic partners17. This program aimed to strengthen the delivery of asthma services through education, training, and practical tools designed for use in community pharmacy settings. More than 400 community pharmacists, representing approximately 28% of CPs in the Republic of North Macedonia were enrolled in the asthma care education project which included interactive workshops on asthma, its management, inhaler techniques education and use of Asthma Respiratory Care (ARC) tools (Asthma Control Test [ACT] and Asthma Slide Rule[ASR]) that was translated into the Macedonian language18. Building on these workshops, structured pharmacist-led interventions were subsequently implemented in community pharmacies. The objective of this research was to evaluate the impact of a structured pharmaceutical care intervention on asthma control among patients managed in community pharmacy settings in North Macedonia. Importantly, evaluating the contribution of pharmacists within this framework may also provide insight into the longer-term feasibility of their active participation in structured asthma care pathways. It assessed asthma control using validated instruments, identified and addressed errors in inhaler technique, and monitored changes in clinical outcomes over time. In addition, it examined the effectiveness of pharmacist-led interventions in enhancing asthma management and emphasized the growing role of CPs as significant contributors to primary respiratory care. Methods Implementation framework This point prevalence evaluation was conducted in community pharmacies across the Republic of North Macedonia. The study is an ongoing, real-world evaluation; therefore, the intervention period (December 2023–September 2024) reflects the active implementation phase of the program, during which all eligible patients entering the service were consecutively offered participation. No control group was included, as the study was designed to evaluate routine pharmacy practice under real-world conditions. It involved patients over 12 years of age with a confirmed asthma diagnosis and aimed to assess asthma control and SABA use, improve inhaler technique, and provide individualized pharmacological and non-pharmacological counselling to support self-management. In the national healthcare system, asthma medications are prescribed by pulmonologists, with follow-up prescriptions subsequently issued by general practitioners (GPs). Patients can then present their prescription at any community pharmacy of their choice to obtain their inhaler, which establishes a point of contact between the pharmacist and the prescribing physicians in supporting optimal asthma care. This initiative represents the practical rollout of a structured pharmaceutical care model within routine pharmacy practice and was part of a broader national effort to standardize asthma care delivery, following CPs training and educational activities organized in collaboration with the IPCRG and Centre for Family Medicine at the Medical Faculty, Ss. Cyril and Methodius University in Skopje in which the Association of private community pharmacies of the Republic of North Macedonia participated actively(Naumovska et al.,18). Assessment of asthma control To evaluate asthma control, the Asthma Control Test (ACT) described at the IPCRG website19 was administered. This validated tool comprises five patient-reported questions related to symptoms and functional limitations over the past four weeks, including daytime and night-time symptoms, activity restriction, reliever (SABA) use, and the patient’s perception of control. Each item is scored from 1 to 5, yielding a total score between 5 and 25, with the following interpretation: Well-controlled asthma: 25 points; Moderately controlled asthma: 20–24 points and Poorly controlled asthma: <20 points and less than 15 very poorly controlled asthma20,21. Patients were invited by the pharmacist to complete the ACT questionnaire online/on paper in the community pharmacy, and their responses were recorded using a Google Forms platform. CPs then reviewed and interpreted the results during the same visit. Evaluation of SABA Use In conjunction with the ACT, CPs used the front side of the Asthma Slide Rule (ASR), a linear visual tool, to facilitate self-assessment and counselling on SABA use. The ASR was made available in Macedonian, translated and adapted by the IPCRG working group, and could be accessed in both English22 and Macedonian23. According to the ASR, patients using <8 puffs of SABA per week fall within the green zone, indicating lower SABA use. Those using 9–23 puffs per week fall within the orange zone, indicating moderate SABA use, while patients using 24–46 puffs per week fall within the red zone, indicating high SABA use. These categories are derived from the ASR as a pragmatic clinical tool to support patient self-assessment and counselling, and do not represent classifications of asthma control. While international guidelines (e.g., GINA) define SABA overuse using specific thresholds, the ASR provides a complementary, practice-oriented framework for identifying patterns of SABA reliance in routine care. Patients marked how often they used their “rescue inhaler” each week, allowing CPs to assess patterns of SABA use using the ASR as a practical, patient-oriented tool developed by the IPCRG. While SABA overuse (commonly defined as >2 uses per week)24, is considered indicative of likely poor disease control the ASR categories were used to support identification of increasing SABA reliance rather than as a measure of asthma control. Additionally, CPs recorded the number of SABA canisters dispensed over the past 12 months, using pharmacy records or patient recall. According to Global Initiative for Asthma (GINA) guidelines (https://ginasthma.org/), and our national Guideline25, patients who used more than three SABA canisters per year were classified as having suboptimal asthma control. Inhaler technique assessment Following the ACT and SABA use discussion, patients were invited to demonstrate their inhaler technique. CPs assessed the accuracy of inhaler technique using device-specific checklists based on the instructions provided in the patient information leaflet of each inhaler, covering key steps such as the inspiratory manoeuvre, coordination, and proper inhaler storage. All CPs used standardized, device-specific inhaler technique checklists based on the manufacturer’s patient information leaflets, following a harmonized assessment approach introduced during pharmacist training. The presence of at least one critical error resulted in classification as incorrect inhaler technique. Any identified errors were corrected immediately through individualized instruction. Educational intervention The visit concluded with a tailored educational session provided by the CPs, including:Pharmacological counselling: Correct use of controller therapy, appropriate use of relievers, and importance of regular follow-up.Non-pharmacological guidance: Allergen and trigger avoidance, encouragement of physical activity, smoking cessation (when applicable) and use of symptom diaries.Motivational and behavioural support: When appropriate, CPs provided lifestyle counselling aimed at improving adherence, preventing complications, and promoting long-term self-management. This included use of the “readiness” side of the ASR tool to assess how important patients felt it was to have a follow-up review and how confident they were in requesting it. Use of supportive tools: Based on need, advice for potential use of peak flow meters or pulse oximeters to monitor asthma symptoms.Referral protocol: Patients with ACT scores <20 and/or SABA overuse were advised to consult their general practitioner or pulmonologist. Pharmacological counselling: Correct use of controller therapy, appropriate use of relievers, and importance of regular follow-up. Pharmacological counselling: Correct use of controller therapy, appropriate use of relievers, and importance of regular follow-up. Non-pharmacological guidance: Allergen and trigger avoidance, encouragement of physical activity, smoking cessation (when applicable) and use of symptom diaries. Non-pharmacological guidance: Allergen and trigger avoidance, encouragement of physical activity, smoking cessation (when applicable) and use of symptom diaries. Motivational and behavioural support: When appropriate, CPs provided lifestyle counselling aimed at improving adherence, preventing complications, and promoting long-term self-management. This included use of the “readiness” side of the ASR tool to assess how important patients felt it was to have a follow-up review and how confident they were in requesting it. Use of supportive tools: Based on need, advice for potential use of peak flow meters or pulse oximeters to monitor asthma symptoms. Motivational and behavioural support: When appropriate, CPs provided lifestyle counselling aimed at improving adherence, preventing complications, and promoting long-term self-management. This included use of the “readiness” side of the ASR tool to assess how important patients felt it was to have a follow-up review and how confident they were in requesting it. Use of supportive tools: Based on need, advice for potential use of peak flow meters or pulse oximeters to monitor asthma symptoms. Referral protocol: Patients with ACT scores <20 and/or SABA overuse were advised to consult their general practitioner or pulmonologist. Referral protocol: Patients with ACT scores <20 and/or SABA overuse were advised to consult their general practitioner or pulmonologist. Statistical analysis Statistical analysis was conducted using the free statistical software Jamovi26. Age was treated as a continuous variable, ACT and ASR scores were analysed as ordinal variables, while gender, accuracy of inhalation technique, and demonstration of inhalation technique were treated as nominal variables. Chi-square test was used to assess associations between variables, and a p-value of <0.05 was considered statistically significant. Where necessary, odds ratios (OR) were calculated using the Haldane–Anscombe correction to account for zero frequencies in contingency tables. No imputation methods were applied for missing follow-up data. Analyses of second and third visits were restricted to patients who returned for reassessment, and these results were not extrapolated to the baseline cohort. Ethical consideration The study was conducted as a practice-based, point prevalence evaluation within community pharmacy settings. Patients were approached during regular pharmacy visits and were informed about the purpose of the evaluation. Verbal informed consent was obtained prior to inclusion. No changes to prescribed therapy were made as part of the study. Pharmacists performed inhaler technique assessment, provided individualized counselling, and conducted follow-up during routine patient interactions. All activities were performed as part of standard pharmaceutical care. Data were collected at each visit using predefined forms. Only non-identifiable information was recorded, including patient initials, visit timing, and relevant clinical parameters. Follow-up visits were linked using these identifiers. Access to collected data was restricted to the research team. Data were stored in anonymized form and used exclusively for analysis of point prevalence outcomes. As this evaluation was based entirely on standard care activities and did not involve a formal interventional protocol, the study was not submitted for institutional review board approval. Results A total of 1247 patients were included in the evaluation. The mean age was 61.2 years (95% CI: 60.43–62.0), with a standard deviation (SD) of 14.12 years (95% CI: 13.58–14.69) and a coefficient of variation (CV) of 23.06%. The age range spanned from 14 to 90 years. Regarding gender distribution, 55.17% were female and 44.83% male. The results of the ACT, ASR (weekly use of SABA), the correctness of inhalation technique, and whether the technique was demonstrated by the CPs are presented in Table 1.Table 1Overview of asthma management indicators among evaluated participants.CategoryNumber of patients (n = 1247)Percentages (%)Confidence interval (95%)Asthma Control Test (ACT)Poorly Controlled33827.1124.58–29.64Moderately Controlled46937.6134.95–40.27Well Controlled44035.2832.65–37.91Asthma Slide Rule (ASR)High SABA use15812.6710.85–14.49Moderate SABA32025.6623.21–28.11Low SABA use76961.6758.97–64.37Inhalation techniqueCorrect101381.2379.04–83.42Incorrect23418.7716.58–20.96Community pharmacists‘ demonstration of inhalation techniqueYes92073.7871.31–76.25No32726.2223.75–28.69 Table 1Overview of asthma management indicators among evaluated participants.CategoryNumber of patients (n = 1247)Percentages (%)Confidence interval (95%)Asthma Control Test (ACT)Poorly Controlled33827.1124.58–29.64Moderately Controlled46937.6134.95–40.27Well Controlled44035.2832.65–37.91Asthma Slide Rule (ASR)High SABA use15812.6710.85–14.49Moderate SABA32025.6623.21–28.11Low SABA use76961.6758.97–64.37Inhalation techniqueCorrect101381.2379.04–83.42Incorrect23418.7716.58–20.96Community pharmacists‘ demonstration of inhalation techniqueYes92073.7871.31–76.25No32726.2223.75–28.69 Overview of asthma management indicators among evaluated participants. A cross-tabulation analysis was conducted to evaluate the association between asthma control levels and the appropriateness of inhalation technique, using both the ACT and the ASR as assessment tools. Incorrect inhalation technique was most common among patients classified as having poorly controlled asthma according to the ACT (139/338, 41.1%), followed by those with moderately controlled asthma (88/469, 18.8%), while it was rare among patients with well-controlled asthma (7/440, 1.6%). These percentages reflect the proportion of incorrect technique within each ACT category. Across the entire evaluated population (N = 1247), 11.1% had incorrect inhaler technique and poorly controlled asthma, 7.1% had incorrect inhaler technique and moderately controlled asthma, and 0.6% had incorrect inhaler technique and well-controlled asthma. While these overall percentages provide a descriptive perspective, they may underestimate the frequency of incorrect technique in smaller subgroups. The χ² test for association was performed on the entire population as an inferential analysis to formally assess the relationship between ACT category and inhalation technique, rather than within individual subgroups, as each subgroup alone would not allow meaningful statistical inference. This association was statistically significant (χ² = 196, p < 0.001; Cramer’s V = 0.396) indicating that the relationship between asthma control and inhalation technique is unlikely to have occurred by chance. The analysis revealed a moderate association, as quantified by Cramer’s V, between the accuracy of inhalation technique and the level of asthma control, as assessed by the ACT score. Odds ratios (OR) were calculated using the moderately controlled group (ACT 20–24 points) as the reference. Patients with poorly controlled asthma (ACT 1–19 points) had significantly lower odds of correct inhalation technique (OR = 0.33; 95% CI: 0.24–0.45), indicating a 67% reduction in the odds of correct technique compared to those with moderate control. In contrast, patients with well-controlled asthma (ACT score = 25) exhibited substantially higher odds of using the inhaler correctly (OR = 14.29; 95% CI: 6.54–31.23). Overall, patients with incorrect inhalation technique were six times more likely to have poorly controlled asthma compared to those with correct technique (moderate and well controlled combined) (OR = 5.98; 95% CI 4.41–8.09, p < 0.001). Similarly, when patients were evaluated using the ASR and found to have SABA overuse, the pharmacist conducted a motivational interview to explore potential reasons for poor status and to optimize therapy. Incorrect inhalation technique was most frequent among patients with high SABA use (81/158, 51.3%), followed by those with moderate SABA use (89/320, 27.8%), and was rare among patients with low SABA use (39/769, 5.1%). These percentages reflect the frequency of incorrect technique within each ASR category. When expressed in relation to the entire evaluated population (N = 1247), these proportions were 6.5, 7.1, and 3.1%, respectively. Although these percentages may underestimate incorrect technique in specific subgroups, they provide an overall general overview, as noted previously for the ACT. This relationship was also statistically significant (χ² = 182, p < 0.001; Cramer’s V = 0.382), indicating a moderate association, based on Cramer’s V, between ASR-defined SABA use categories and inhalation technique. Further analysis using odds ratios, with the moderate SABA use group as the reference, demonstrated that patients with poorly controlled asthma had significantly lower odds of correct inhalation technique (OR = 0.37; 95% CI: 0.25–0.54), corresponding to a 63% reduction in the odds of correct technique. In contrast, patients with low SABA use compared to moderate SABA use group exhibited substantially higher odds of correct inhalation technique (OR = 4.24; 95% CI: 2.98–6.05). Moreover, patients with high SABA use were significantly more likely to use incorrect inhalation technique, as evidenced by an odds ratio of 6.43 (95% CI: 4.50–9.18) when compared to those with moderate or low SABA use combined. Of the total 1247 patients evaluated, 127 returned to the same community pharmacy for follow-up assessments during the evaluation period, representing a subset of the initial cohort who attended consecutive visits. Their mean age was 63.23 years (95% CI: 60.91–65.55), with a SD of 13.22 (95% CI: 11.77–15.08) and a CV of 20.91%. The age range was 16 to 88 years, and 51.18% were females while 48.82% were males. During the third visit, 56 patients returned for further assessment. Of these, 48.21% were female and 51.79% were male, with a mean age of 62.55 years (95% CI: 58.56–66.55), a SD of 14.79 years (95% CI: 12.59–18.35), a CV of 23.87%, and an age range of 16 to 87 years. An overview of asthma management indicators among participants who underwent the second and third follow-up visits is presented in Table 2.Table 2Overview of asthma management indicators among participants at the second and third follow-up visits.CategorySubcategorySecond visit (n = 127)Third visit (n = 56)Number%95% CINumber%95% CIAsthma Control Test (ACT)Poorly controlled1310.244.9–15.523.570–8.4Moderately controlled5140.1631.6–48.71832.1420–44.3Well controlled6349.6140.9–58.33664.2951.8–76.7Asthma Slide Rule (ASR)High SABA use43.150.1–6.4///Moderate SABA use2620.4713.4–27.5610.712.6–18.8Low SABA use9776.3868.9–83.85089.2981.1–97Inhalation techniqueCorrect11388.9883.5–94.45598.2194.7–100Incorrect1411.025.6–16.611.790–5.3Pharmacists’ demonstration of inhalation techniqueYes7861.4252.9–69.92239.2926.5–52No4938.5830.1–47.13460.7148–73.5 Table 2Overview of asthma management indicators among participants at the second and third follow-up visits.CategorySubcategorySecond visit (n = 127)Third visit (n = 56)Number%95% CINumber%95% CIAsthma Control Test (ACT)Poorly controlled1310.244.9–15.523.570–8.4Moderately controlled5140.1631.6–48.71832.1420–44.3Well controlled6349.6140.9–58.33664.2951.8–76.7Asthma Slide Rule (ASR)High SABA use43.150.1–6.4///Moderate SABA use2620.4713.4–27.5610.712.6–18.8Low SABA use9776.3868.9–83.85089.2981.1–97Inhalation techniqueCorrect11388.9883.5–94.45598.2194.7–100Incorrect1411.025.6–16.611.790–5.3Pharmacists’ demonstration of inhalation techniqueYes7861.4252.9–69.92239.2926.5–52No4938.5830.1–47.13460.7148–73.5 Overview of asthma management indicators among participants at the second and third follow-up visits. The comparative results of the ACT and ASR assessments across the three visits are visualized in Fig. 1, providing a clearer overview of disease control over time, with the caveat that these figures depict only patients who attended follow-up visits and may not reflect the outcomes of the entire cohort. Figure 2 illustrates the progressive improvement in inhalation technique accuracy at each visit. These figures present repeated point-prevalence measurements from a subset of patients who attended follow-up visits, rather than a fully prospective longitudinal cohort. Furthermore, the time interval between visits was documented. Between the first and second visit, ~ 82% of patients had a follow-up interval 1–2 months, while ~14% attended within 3–4 months, with five patients (~4%) exceeding 4 months. Between the second and third visit, 91% of patients attended within 1–2 months, while five patients (~9%) had an interval longer than 3 months. Following the evaluation of patients’ inhalation techniques, a demonstration of the correct method was provided, accompanied by a pharmaceutical intervention that included counselling on proper inhaler use, non-pharmacological measures, and other key aspects of pharmaceutical care aimed at optimizing asthma management within this real-world evaluation context. The results indicate that asthma control, as measured by both the ACT and ASR scores, improved progressively across the three visits among patients who attended follow-up, with a decrease in the proportion of patients classified as poorly or moderately controlled, and an increase in those achieving well-controlled status. Crosstabulation analyses of ACT scores between the first and second visits, as well as between the second and third visits, revealed statistically significant differences, with chi-squared values of 47.3 and 31.7, respectively (p < 0.001 for both) restricted to patients who attended both visits. For the ASR, significant changes were observed between the first and second visits (χ² = 41.2, p < 0.001). However, no statistically significant difference was found between the second and third visits.Fig. 1ACT and ASR scores across visits.a First and second visit of 127 patients assessed at both visits and b across first, second and third visit of 56 patients.Fig. 2Accuracy of inhalation technique across visits.a First and second visit of 127 patients assessed at both visits and b across first, second and third visit of 56 patients assessed at all three visits. ACT and ASR scores across visits. a First and second visit of 127 patients assessed at both visits and b across first, second and third visit of 56 patients. Accuracy of inhalation technique across visits. a First and second visit of 127 patients assessed at both visits and b across first, second and third visit of 56 patients assessed at all three visits. At the first assessment, 91 of the 127 patients who were followed up at the second visit (71.7%) were able to use the inhaler correctly. Among these 127 patients, 111 (87.4%) had accepted the demonstration of correct inhalation technique during their initial consultation. Following this educational intervention, a substantial improvement was observed at the follow-up, with 113/127 patients (89%) demonstrating correct technique, including 100 of those who had received the demonstration. Of the 56 patients who attended a third visit, 51 (91.1%) had received the demonstration during their first consultation, while 27 (48.2%) accepted it during the second visit. Importantly, of these 56 patients, 21 initially demonstrated incorrect technique at the first visit. This number declined to 6 at the second visit and further decreased to only 1 patient at the third visit. These findings clearly indicate a progressive improvement in inhalation technique over time, highlighting the positive impact of targeted patient education and hands-on demonstration, as observed in this real-world pharmacy service evaluation. Significant associations between asthma control and correct inhalation technique observed at the first visit persisted during the second visit for both the ACT and the ASR. At the second visit, the ACT showed a significant relationship with inhalation technique accuracy (χ² = 25.3, df = 2, p < 0.001; Cramer’s V = 0.446). Patients with poorly controlled asthma (ACT 1–19 points) had significantly lower odds of using the inhaler correctly compared to those with moderate control (OR = 0.22; 95% CI: 0.06–0.84), and were over 11 times more likely to demonstrate incorrect technique (95% CI: 3.01–41.15) when compared to moderately and well controlled combined. By the third visit, however, this association was no longer statistically significant, probably reflecting improvements in technique over time. Similarly, the ASR assessment at the second visit revealed a significant association with inhalation technique (χ² = 35.1, df = 2, p < 0.001; Cramer’s V = 0.526). Patients with low SABA use had higher odds of correct inhaler use compared to those with moderate SABA use (OR = 2.86; 95% CI: 0.74–11.04), while patients with high SABA use were found to be approximately 97 times more likely to use incorrect technique (OR = 97.3; 95% CI: 4.89–1933.5) compared to combined groups with moderate and low SABA use. As with the ACT, no significant association was detected at the third visit, coinciding with the overall improvement in inhalation technique. The relationship between inhalation technique demonstration and subsequent patient performance was also evaluated across visits. Although the difference was not statistically significant, the calculated odds ratio suggested that patients who received a demonstration had approximately twice the odds of correct inhalation technique (OR = 2.1; 95% CI: 0.52–8.52), indicating a positive trend. As during third visit only one incorrect inhalation technique was observed the odd ratio could not be calculated. As part of the service, all patients received a structured educational intervention delivered by community pharmacists, including pharmacological and non-pharmacological counselling, inhaler technique training if accepted, and referral recommendations when appropriate. However, the uptake and outcomes of these individual components were not systematically recorded and are therefore not reported quantitatively. Discussion This real-world study showed that a unique pharmaceutical care intervention can improve asthma outcomes. The study was a point prevalence evaluation that reflected a snapshot at the time of pharmaceutical consultation. The consultation was an intervention focused on a blend of inhalation technique and other patient counselling, and was delivered only in a pharmacy setting. Out of 1247 included patients, only about one-third had well-controlled asthma according to the ACT (~35%), while 61% were classified as having low SABA use according to the ASR. Incorrect inhalation technique was observed in nearly one-fifth of participants (~19%), highlighting a key modifiable target for intervention. A strong and statistically significant association was observed between inhalation technique and asthma control. Patients with well-controlled asthma had up to 14 times higher odds of correct inhaler use compared with those with moderately controlled asthma, while patients with poorly controlled asthma had up to six-fold higher odds of incorrect inhaler use compared with the combined group of better-controlled patients. These findings underline inhalation technique as a significant determinant of asthma control. The differences in ACT and ASR suggest that some patients may underuse reliever medication despite poor symptom control, while others may report higher symptom burden than reflected by SABA use alone. These differences highlight the complementary value of using both ACT and ASR in clinical practice, as each captures distinct dimensions of asthma control, subjective symptom burden (ACT)27 versus SABA use behaviour (ASR)28. The observed differences between ACT and ASR are often underpinned by adherence-related factors, as patients’ perceptions, beliefs, and behaviours strongly influence both symptom reporting and medication use29. Adherence is impeded by perceptual barriers, such as doubting the need for medication in the absence of symptoms, underestimating the significance of symptoms, concerns about drug-related side effects, and a lack of understanding of the importance of asthma control30. Lack of adherence to controller therapy and poor inhaler technique are the most commonly reported patient-related factors associated with poor asthma control. The CPs role extended beyond merely demonstrating the inhalation technique. The intervention included individualized counselling that addressed non-pharmacological strategies such as smoking cessation, environmental trigger avoidance, promotion of physical activity, and strategies to improve adherence. Additionally, other important aspects of pharmaceutical care were addressed, including assessment and support for medication adherence, management of side effects, education on drug interactions and proper medication storage, guidance on regular disease monitoring, recognition and management of acute exacerbations, and advice on when to seek medical help. Additional insights from point prevalence follow-up data were obtained from 127 patients who returned for at least two visits and 56 patients who completed all three visits. These data provided an overview of intervention-related trends over time. However, the primary analysis focuses on point prevalence associations at the time of consultation. Across these visits, improvements in asthma control were observed based on both ACT and ASR scores, with a reduction in poorly and moderately controlled asthma and an increase in well-controlled patients. Perhaps most notably, the accuracy of inhalation technique improved substantially with each visit, rising from ∼72% at baseline to ∼89% at the second visit, while among patients who attended all three visits, accuracy increased from ∼63% at the first visit to∼89% at the second and ∼98% by the third visit. These findings indicate that repeated pharmaceutical care interventions may be associated with improvements in inhalation technique and asthma control over time. However, the primary analysis remains based on point prevalence associations at the time of consultation. Although not all comparisons reached statistical significance, the overall trend favoured patients who received pharmacist-led interventions, indicating a consistent positive effect on asthma-related outcomes. These findings support the role of CPs in improving key aspects of asthma management, particularly inhaler technique and adherence-related behaviours. Improved adherence to prescribing guidelines represents an important mechanism underlying these outcomes. Pharmacists in this study based their recommendations on established guidelines, which is consistent with previous evidence demonstrating that pharmacist involvement enhances guideline-concordant care and is associated with better asthma control. These findings are in line with Serhal et al.31, who demonstrated that pharmacist-led education significantly improved adherence, ACT scores, and lung function, particularly when interventions were tailored to patients’ baseline adherence and control levels. Similarly, it has been found that CPs, using structured protocols over four consultations, significantly improved patients’ asthma control and quality of life, highlighting the value of pharmacist engagement in long-term asthma care32. Kovačević et al.33, also, showed that targeted pharmacist counselling led to significant gains in asthma control and adherence, with nearly one-fifth of patients moving from poorly to well-controlled asthma within three months. A review by Mahmoud et al. concluded that CPs are well-positioned to improve asthma outcomes through education, inhaler technique correction, and collaborative care reinforcing the holistic, non-pharmacological impact observed in this research34. Moreover, as there is a policy push to invest in primary care for chronic respiratory diseases2, there is a growing need for studies demonstrating how best to deliver these services, including the optimal skill mix within primary care teams. Taken together, these findings reinforce the clinical value of pharmacist-led interventions in asthma care. The results of this study provide evidence that structured pharmaceutical care can support better disease monitoring, improve patient engagement, and contribute to more effective asthma management within primary care settings. In addition, structured documentation of pharmaceutical care activities within routine practice may facilitate communication and continuity of care among healthcare professionals. Strengths and limitations The study included a large sample size providing real-world evidence and the use of validated tool (ACT) and practical, patient-oriented tool (ASR) allowed for a multidimensional assessment of asthma control. Conducted in real-world pharmacy settings, the results demonstrated the feasibility of integrating structured pharmaceutical care into routine community pharmacy practice. As this was a real-world service evaluation rather than a controlled clinical trial, the point prevalence follow-up involved only those patients who returned for subsequent visits, which reflects typical real-life attendance patterns rather than a pre-selected cohort. The point prevalence follow-up of a patient subgroup provided evidence of sustained improvements over time, while the holistic nature of the intervention combining inhaler training, lifestyle counselling, and adherence support underscored the CPs expanding role in primary care. This research has some limitations. Participation was voluntary for both patients and community pharmacists, and no incentives were provided, introducing potential selection bias. The lack of a control group restricts causal interpretation of the findings. Improvements in asthma control may have resulted from factors not systematically measured in this study, such as changes in environmental exposures, comorbidities, or socioeconomic determinants. Outcomes were based on self-reported measures without objective clinical validation. Additionally, the follow-up period was short for most patients, and smaller sample sizes in later visits limited the statistical power of subgroup analyses. Additionally, not all patients attended follow-up visits, and the smaller sample sizes at later visits limited the statistical power of subgroup analyses; this is expected in real-world settings and should be considered when interpreting point prevalence outcome. Conclusion The findings of this research support the conclusion that structured pharmaceutical care interventions, particularly those involving repeated education and follow-up of patients, can significantly enhance both inhaler technique and asthma control. Although correct inhaler use alone may not be sufficient to fully control asthma, it is a foundational component. When inhaler instruction is combined with personalized counselling and non-pharmacological guidance, the community pharmacist’s role can meaningfully influence disease outcomes. This initiative demonstrates that integrating structured pharmaceutical care into routine asthma management leads to measurable improvements in patient outcomes, validating the importance of community pharmacists as frontline partners in chronic disease management.